Previous 10 | Next 10 |
Safety, Tolerability and Pharmacokinetics (“PK”) Primary Endpoints Met Reductions in Liver Transaminases Indicate Dose-Related Improvements in Key NASH Biomarker Concentration-Effect Relationship Demonstrated for ALT Reductions Multiomic Analyses an...
Biotech Penny Stocks Remain A Focus Heading Into Q3 2021 Penny stocks are well known for their high risk and high reward potential. There aren’t many places where you can buy into an early-stage company, see shares rise 100% or more, and take profit all within a single day or wee...
EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that...
Hepion Pharmaceuticals (HEPA) will join the Russell Microcap index, effective after the U.S. market opens on June 28. “Being included among the companies that comprise the Russell indexes is a significant milestone for Hepion, which, we believe reflects the progress we are making to in...
EDISON, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steat...
Hepion Pharmaceuticals is a biopharmaceutical company focused on drug therapy treatment for chronic liver diseases in the US. It's currently developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progressio...
EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that ...
EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholic st...
Analysts Say Buy These Penny Stocks; Do You Agree? Many have taken an interest in penny stocks over the last year. By definition, this term refers to stocks that trade under $5. Inherently these stocks are very risky and volatile in nature. This can be a good thing or a bad thing, depen...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The bubble has burst. Penny stocks are falling like autumn leaves. The Reddit crowd and the day-trading community have learned a few difficult but needed lessons. First, it’s difficult to make money in the stock ma...
News, Short Squeeze, Breakout and More Instantly...
Hepion Pharmaceuticals Inc. Company Name:
HEPA Stock Symbol:
NASDAQ Market:
Hepion Pharmaceuticals Inc. Website:
Gaucho Group Holdings Inc. (VINO) is expected to report for Q1 2024 Tosoh Corporation (TOSCF) is expected to report for Q4 2024 Adidas AG ADR - Level I (ADDYY) is expected to report $0.69 for Q1 2024 MicroCloud Hologram Inc. (HOLO) is expected to report for Q1 2024 Universal Enter...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
A look at the top 10 most actives in the United States AGBA Group Holding Limited (AGBA) rose 100.0% to $2.5 on volume of 201,539,290 shares PROSHARES TRUST (SQQQ) fell 2.9% to $12.47 on volume of 154,254,858 shares Tesla Inc. (TSLA) fell 3.4% to $142.05 on volume of 106,267,579 shares ...